Cellectar Biosciences, Inc. (CLRB)

Nasdaq: CLRB · Pharmaceutical Preparations · Florham Park, NJ · filing with the SEC since 2004

Grade5.0

◀ Past 3.0● Present 4.8▶ Future 6.3

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Report filed	Mar 4, 2026	Mar 13, 2025	Mar 27, 2024	Mar 9, 2023	Mar 21, 2022	Mar 2, 2021	Mar 9, 2020	Feb 26, 2019	Mar 21, 2018	Mar 15, 2017
Research and development	11,498,761	26,136,246	27,266,276^r	18,265,711^r	17,586,469	10,140,681	8,996,058	6,835,229	9,465,666	4,750,414
General and administrative	11,481,083	25,641,452	11,694,367^r	10,548,062^r	6,544,811	5,149,668	5,182,566	4,820,073	4,135,304	4,699,338
Total costs and expenses	22,979,844	51,777,698	38,960,643	28,813,773	24,131,280	15,290,349	14,178,624	13,330,764	13,600,970	9,449,752
Operating income	-22,979,844	-51,777,698	-38,960,643	-28,813,773	-24,131,280	-15,290,349	-14,178,624	-13,330,764	-13,600,970	-9,449,752
Interest income (expense), net	435,100	1,210,853	387,147	152,519	2,284	10,897	42,712	29,687	16,605	7,897
Total non-operating income (expense)	1,188,807	7,262,252	-3,869,967^r	-3,038,845^r	8,918	196,177	85,712	91,737	38,680	3,269,426
Income before income taxes	-21,791,037	-44,515,446	-42,830,610^r	-31,852,618^r	-24,122,362	·	·	·	·	·
Income tax expense	·	66,000	-60,000	-60,000	·	·	0	0	0	0
Net income	-21,791,037	-44,581,446	-42,770,610^r	-31,792,618^r	-24,122,362	-15,094,172	-14,092,912	-13,239,027	-13,562,290	-6,180,326
Net income to common shareholders	·	·	·	·	·	·	-14,092,912	-15,480,822	-15,011,235	-9,360,307
Earnings per share, basic	-8.35	-36.52^r	-105.00^rb	-135.30^rb	-130.50^rb	-22.80^b	·	·	·	·
Earnings per share, diluted	-8.35	-41.89^r	-105.00^rb	-135.30^rb	-130.50^rb	-55.20^b	·	·	·	·
Earnings per share, basic and diluted	·	·	·	·	·	-22.80^b	-55.20^b	-156.90^b	-321.00^rb	-64.20^rb
Weighted average shares, basic	2,608,317	1,220,749^r	407,386^b	235,189^b	185,052^rb	660,422^b	·	·	·	·
Weighted average shares, diluted	2,608,317	1,238,125^r	407,386^b	235,189^b	185,052^rb	660,422^b	·	·	·	·
Weighted average shares, basic and diluted	·	·	·	·	·	660,422^b	255,836^b	98,732^b	46,771^rb	145,554^rb

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-30 reverse split of Jun 2025.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense

General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense

Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses

Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss

Interest income (expense), net interest earned less interest paid, outside the businessus-gaap:InterestIncomeExpenseNonoperatingNet

Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense

Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit

Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss

Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic

Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted

Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted

Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic

Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

SI Assistanton CLRB · research, not advice